4C Recap - OncoSil Medical Ltd's Quarterly Update and Future...

4C Recap - OncoSil Medical Ltd's Quarterly Update and Future

• Board Leadership and Strategic Vision: OncoSil's board has welcomed two significant members.

• Mr. Douglas Cubbin now chairs the board following Mr. Otto Buttula's retirement, providing extensive experience from a successful tenure at Telix Pharmaceuticals.

• Dr. Ga briel Liberatore, with his impressive biopharmaceutical background, has joined as a Non-Executive Director, promising to infuse the board with fresh strategic insights.

• Clinical Trials and Expanding Operations: The company is advancing a pivotal trial in Germany, with hopes that a positive outcome will establish the OncoSil™ device as a reimbursable treatment, enhancing its commercial viability in the European market.

• At the forefront of industry engagement, OncoSil made a significant impact at the EANM Congress in Vienna, promoting the device and fostering relationships that could lead to distribution partnerships.

• In Spain, the uptake of OncoSil™ is on the rise, with more centers treating patients and contributing to an expanding patient treatment count, a testament to the device's growing footprint in Europe.

• The OSPREY registry's enrollment has progressed, underscoring the device's application in the real-world clinical setting and its potential impact on standard care practices.In Italy, the patient base for OncoSil™ treatments has broadened, indicating the device's acceptance and usage beyond initial clinical settings.

• Israel's Hadassah Hospital has successfully treated a fourth patient, showcasing the device's international reach and the hospital's dedication to innovative treatments.

• The TRIPP-FFX Clinical Study is gathering momentum, with patient numbers increasing. This study is crucial for expanding the device's indication to include its usage alongside FOLFIRINOX chemotherapy, potentially broadening its therapeutic scope.

• Regulatory Engagement:Ongoing dialogues with the FDA aim to expedite the application for the OncoSil™ device to treat distal cholangiocarcinoma, reflecting the company's commitment to navigating the complex regulatory landscape.

• Financial Management: OncoSil reported a solid cash position, though there was a notable decrease from the previous quarter. The report details substantial investments in staff expertise and the research and development of the OncoSil™ device.The company is executing a cost-optimization strategy, aiming to align expenditures with growth and ensuring a more extended financial runway to support upcoming clinical and commercial milestones.

• Strategic Development: The company is not standing still on the strategic front, actively seeking out and evaluating potential partnership opportunities, with a view to possibly strengthening its market position and enhancing shareholder value.

OncoSil Medical Ltd is navigating a period of strategic leadership changes, active clinical trials with positive progression, and robust operational activities.

With a proactive financial strategy and potential strategic partnerships on the horizon, OncoSil is positioning itself for a dynamic phase of growth and market expansion.